March 1, 2025 06:00 AM EST
Weekly

The top 100 biotech in­vestors; FDA vac­cine meet­ing can­celed; Can Bill An­der­son save Bay­er?; and more

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Good morn­ing and rab­bit rab­bit as we be­gin the month of March. It was an­oth­er busy week in the world of bio­phar­ma so let’s jump …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times